American Journal of Cardiology
Volume 98, Issue 5 , Pages 641-643 , 1 September 2006

Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia

Received 2 January 2006 ,Revised 9 March 2006 ,Accepted 13 March 2006.

References 

  1. Jialal I , Devaraj S . Inflammation and atherosclerosis (the value of the high-sensitivity C-reactive protein assay as a risk marker) . Am J Clin Pathol . 2001;116(suppl):S108–S115
  2. Rifai N , Ridker PM . High-sensitivity C-reactive protein (a novel and promising marker of coronary heart disease) . Clin Chem . 2001;47:403–411
  3. Insull W, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia (a 24-week randomized controlled trial) . Mayo Clin Proc . 2001;76:971–982
  4. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (Cholestagel) (a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects) . Arch Intern Med . 1999;159:1893–1900
  5. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia . Am J Med . 2001;110:352–360
  6. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia . Clin Cardiol . 2001;24:467–474
  7. Hunninghake D , Insull W , Toth P , Davidson D , Donovan JM , Burke SK . Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively . Atherosclerosis . 2001;158:407–416
  8. McKenney J , Jones M , Abby S . Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia . Curr Med Res Opin . 2005;21:1403–1412
  9. Devaraj S , Jialal I . Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients . Free Radic Biol Med . 2000;29:790–792
  10. Devaraj S , Jialal I . Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications (the effect of alpha-tocopherol supplementation) . Circulation . 2000;102:191–196
  11. Jialal I , Stein D , Balis D , Grundy SM , Adams-Huet B , Devaraj S . Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels . Circulation . 2001;103:1933–1935
  12. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events . N Engl J Med . 2001;344:1959–1965
  13. Ridker PM , Hennekens CH , Buring JE , Rifai N . C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women . N Engl J Med . 2000;342:836–843
  14. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia (a prospective, randomized, double-blind trial) . Circulation . 2003;107:2409–2412

 This study was supported by Grant NIHK24AT00596 from Sankyo Pharma Incorporated, Parsippany, New Jersey.

PII: S0002-9149(06)00992-1

doi: 10.1016/j.amjcard.2006.03.043

American Journal of Cardiology
Volume 98, Issue 5 , Pages 641-643 , 1 September 2006

Article Tools

* Image Usage & Resolution